{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:54:07Z","timestamp":1773230047848,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-21-045-01-CPHPS"],"award-info":[{"award-number":["RSG-21-045-01-CPHPS"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN2612018000151"],"award-info":[{"award-number":["HHSN2612018000151"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","award":["HHSN2612018000091"],"award-info":[{"award-number":["HHSN2612018000091"]}],"id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1NU58DP007156"],"award-info":[{"award-number":["1NU58DP007156"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014479","name":"Georgia Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.urolonc.2025.09.008","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:04:31Z","timestamp":1759993471000},"page":"721.e9-721.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An opportunity to save? SBRT is less costly than IMRT for intermediate-risk prostate cancer"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1382-2136","authenticated-orcid":false,"given":"Vanessa N.","family":"Pe\u00f1a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwaseun","family":"Orikogbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyton A.","family":"Skupin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Alameddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan G.","family":"Yabes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Beichner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam C.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay M.","family":"Sabik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce L.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.urolonc.2025.09.008_bib0001","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2013.53.8652","article-title":"Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity","volume":"32","author":"Yu","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.09.008_bib0002","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10196","key":"10.1016\/j.urolonc.2025.09.008_bib0003","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.008_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.008_bib0005","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.euo.2023.10.019","article-title":"Long-term outcomes from a phase 1 dose escalation study using stereotactic body radiotherapy for patients with low- or intermediate-risk prostate cancer","volume":"7","author":"Moore","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"15","key":"10.1016\/j.urolonc.2025.09.008_bib0006","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.urolonc.2025.09.008_bib0007","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jamaoncol.2023.4267","article-title":"Increasing use of shorter-course radiotherapy for prostate cancer","volume":"9","author":"Yu","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-020-05656-x","article-title":"Radiation oncologists\u2019 attitudes and beliefs about intensity-modulated radiation therapy and stereotactic body radiation therapy for prostate cancer","volume":"20","author":"Jacobs","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.008_bib0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijrobp.2023.11.043","article-title":"Trends in utilization and Medicare spending on short-course radiation therapy for breast and prostate cancer: an episode-based analysis from 2015 to 2019","volume":"119","author":"Patel","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.urolonc.2025.09.008_bib0010","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/cncr.30101","article-title":"Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer","volume":"122","author":"Halpern","year":"2016","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2025.09.008_bib0011","first-page":"e186","article-title":"Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer","volume":"18","author":"Hodges","year":"2012","journal-title":"Am J Manag Care"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.008_bib0012","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/cncr.29743","article-title":"Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer","volume":"122","author":"Laviana","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.09.008_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2012.00081","article-title":"Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer","author":"Parthan","year":"2012","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.008_bib0014","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/COC.0b013e31827a7d2a","article-title":"Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer","volume":"37","author":"Sher","year":"2014","journal-title":"Am J Clin Oncol: Cancer Clinical Trials"},{"issue":"8","key":"10.1016\/j.urolonc.2025.09.008_bib0015","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/00005650-199308000-00006","article-title":"Potential for cancer related health services research using a linked Medicare-tumor registry database","volume":"31","author":"Potosky","year":"1993","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.008_bib0016","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2014.01.105","article-title":"Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer","volume":"192","author":"Filson","year":"2014","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.008_bib0017","doi-asserted-by":"crossref","first-page":"37.e21","DOI":"10.1016\/j.urolonc.2019.09.031","article-title":"Patterns of stereotactic body radiation therapy: the influence of lung cancer treatment on prostate cancer treatment","volume":"38","author":"Jacobs","year":"2020","journal-title":"Urolog Oncol: Semin Origin Investig"},{"key":"10.1016\/j.urolonc.2025.09.008_bib0018","series-title":"Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care","year":"2003"},{"issue":"12","key":"10.1016\/j.urolonc.2025.09.008_bib0019","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.urolonc.2025.09.008_bib0020","unstructured":"Centers for Medicare and Medicaid Services. (2025). Carrier Line Pricing Locality code. ResDAC. https:\/\/resdac.org\/cms-data\/variables\/carrier-line-pricing-locality-code. Accessed 1 Dec. 2024."},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.008_bib0021","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"key":"10.1016\/j.urolonc.2025.09.008_bib0022","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1200\/JCO.2017.75.5371","article-title":"journal of clinical oncology comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer","volume":"36","author":"Pan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.008_bib0023","article-title":"Model-based cost-effectiveness analysis of external beam radiation therapy for the treatment of localized prostate cancer: a systematic review","volume":"17","author":"Abreha","year":"2019","journal-title":"Cost Effectiv Resource Alloc"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.008_bib0024","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.urolonc.2016.06.003","article-title":"Maximizing resources in the local treatment of prostate cancer: a summary of cost-effectiveness studies","volume":"35","author":"Muralidhar","year":"2017","journal-title":"Urolog Oncol: Sem Orig Investig"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.008_bib0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40258-014-0106-9","article-title":"Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013","volume":"12","author":"Amin","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.008_bib0026","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brachy.2021.06.148","article-title":"Trends and variations in utilization and costs of radiotherapy for prostate cancer: a SEER medicare analysis from 2007 through 2016","volume":"21","author":"Mukherjee","year":"2022","journal-title":"Brachytherapy"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.008_bib0027","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.prro.2020.02.014","article-title":"Costs and complications after a diagnosis of prostate cancer treated with time-efficient modalities: an analysis of national medicare data","volume":"10","author":"Tang","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.urolonc.2025.09.008_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.889132","article-title":"Stereotactic body radiotherapy: hitting harder, faster, and smarter in high-risk prostate cancer","volume":"12","author":"Correa","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.09.008_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2025.09.008_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.852844","article-title":"Patient-reported financial burden following stereotactic body radiation therapy for localized prostate cancer","volume":"12","author":"Sholklapper","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.09.008_bib0031","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00066-017-1115-z","article-title":"Signifikant bessere patientencompliance bei hypofraktionierter im vergleich zu konventionell fraktionierter adjuvanter Strahlentherapie des Mammakarzinoms: ergebnisse einer unizentrischen retrospektiven studie","volume":"193","author":"Rudat","year":"2017","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.1016\/j.urolonc.2025.09.008_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2024.07.051","article-title":"Stereotactic body radiation adoption impacts prostate cancer treatment patterns","author":"Stencel","year":"2024","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2025.09.008_bib0033","unstructured":"CMS Releases 2023-2032 National Health Expenditure Projections.\u201d CMS.Gov, Centers for Medicare and Medicaid Services, 12 June 2024, https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-releases-2023-2032-national-health-expenditure-projections. Accessed October 10, 2024."},{"key":"10.1016\/j.urolonc.2025.09.008_bib0034","unstructured":"Cancer of the Prostate - Cancer Stat Facts.\u201d Surveillance, Epidemiology, and End Results Program, National Cancer Institute, 21 Apr. 2025, https:\/\/www.seer.cancer.gov\/statfacts\/html\/prost.html. Accessed October 1, 2024."},{"key":"10.1016\/j.urolonc.2025.09.008_bib0035","unstructured":"Lindstrom R, Keisler-Starkey K, Bunch L. \u201cPercentage of Older Adults with Both Private Health Insurance and Medicare Decreased from 2017 to 2022.\u201d Census.Gov, United States Census Bureau, 13 June 2024, https:\/\/www.census.gov\/library\/stories\/2024\/04\/older-adults-health-coverage.html. Accessed 19 Dec. 2024."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:50:51Z","timestamp":1773154251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925003795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1078143925003795"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.09.008","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An opportunity to save? SBRT is less costly than IMRT for intermediate-risk prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}